On-Q-ity, a company developing diagnostics that analyze circulating tumor cells to guide treatment strategies for various cancers, announced that its board of directors has appointed Michael Stocum as president and CEO.
Stocum is president and founder of Personalized Medicine Partners, a firm that provides strategic advice to drug and diagnostic companies. Previously, at GlaxoSmithKline, Stocum led the biomarker business strategy for several cancer drugs.
Stocum's appointment comes after Mara Aspinall, founder and former CEO of Waltham, Mass.-based On-Q-ity, left the company last year to become president of Roche subsidiary Ventana Medical Systems.
In addition to Stocum's appointment, the board determined that Walt Carney, formerly On-Q-ity's chief scientific officer, will become the firm's scientific adviser.